Purpose: Use of high global warming potential propellants (eg, 1,1,1,2-tetrafluoroethane [HFA-134a]) in pressurized metered-dose inhalers (pMDIs) is being phased down. Extrafine formulation of beclometasone dipropionate (BDP)/formoterol fumarate (FF), approved for the treatment of asthma or chronic obstructive pulmonary disease via HFA-134a propellant pMDI, is being reformulated using the low global warming potential propellant 1,1-difluoroethane (HFA-152a). Two studies compared BDP/FF pharmacokinetics delivered via pMDI using HFA-152a versus HFA-134a.
Switching to a Low Global Warming Potential Propellant in a Pressurized Metered-Dose Inhaler Does Not Affect the Pharmacokinetics of Combined Beclometasone Dipropionate/Formoterol Fumarate / Almeida, M., Salvadori, M., Corradi, M., De Ridder, T., Praet, N., Viaud, I., Varoli, G., Girardello, L., Cappellini, G., Viganò, L.V., Mathews, K.S., Poli, G.. - In: CLINICAL THERAPEUTICS. - ISSN 0149-2918. - 48:8(2026), pp. 757-763. [10.1016/j.clinthera.2026.04.009]
Switching to a Low Global Warming Potential Propellant in a Pressurized Metered-Dose Inhaler Does Not Affect the Pharmacokinetics of Combined Beclometasone Dipropionate/Formoterol Fumarate
Corradi M.Writing – Original Draft Preparation
;
2026-01-01
Abstract
Purpose: Use of high global warming potential propellants (eg, 1,1,1,2-tetrafluoroethane [HFA-134a]) in pressurized metered-dose inhalers (pMDIs) is being phased down. Extrafine formulation of beclometasone dipropionate (BDP)/formoterol fumarate (FF), approved for the treatment of asthma or chronic obstructive pulmonary disease via HFA-134a propellant pMDI, is being reformulated using the low global warming potential propellant 1,1-difluoroethane (HFA-152a). Two studies compared BDP/FF pharmacokinetics delivered via pMDI using HFA-152a versus HFA-134a.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
